Birchview Capital’s Keros Therapeutics KROS Stock Holding History

Birchview Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,000	Closed	-$153K	–	75
2025 Q1	$153K	Hold	15,000	–	–	0.13%	55
2024 Q4	$237K	Buy	15,000 +8,000	+114%	+$416K	0.19%	54
2024 Q3	$406K	Hold	7,000	–	–	0.35%	31
2024 Q2	$320K	Hold	7,000	–	–	0.3%	43
2024 Q1	$463K	Hold	7,000	–	–	0.38%	36
2023 Q4	$278K	Hold	7,000	–	–	0.22%	43
2023 Q3	$223K	Hold	7,000	–	–	0.19%	45
2023 Q2	$281K	Hold	7,000	–	–	0.21%	47
2023 Q1	$299K	Hold	7,000	–	–	0.23%	44
2022 Q4	$336K	Buy	+7,000	New	+$327K	0.24%	41

Other funds holding KROS

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Birchview Capital's KROS Position: Q2 2025 in Review

Birchview Capital sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 15,000 shares — an estimated $153K sold.

Birchview Capital first reported a position in KROS in Q4 2022 and held it in 10 quarters. The position peaked at $463K in Q1 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

Birchview Capital reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
Birchview Capital sold 15,000 Keros Therapeutics shares in Q2 2025, an estimated $153K.
Birchview Capital first reported a position in Keros Therapeutics in Q4 2022 and held it in 10 quarters.
Birchview Capital's Keros Therapeutics position peaked at $463K in Q1 2024.
139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Birchview Capital's 13F filing for Q2 2025, filed 14 Aug 2025.